At a glance
ClinicalIndex Comparison RecordN/ACompleted· 172 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Trial on Long Responses in Patients With Advanced Non-Small Cell Lung Cancer Treated in Second-Line With Erlotinib
In Brief
An observational study for Non-Small Cell Lung Cancer. Completed, enrolled 172 participants across 39 sites.
Detailed Summary
This multicenter, retrospective and prospective observational, cohort study will examine the effect of second-line Tarceva treatment on long response in non-small cell lung cancer (NSCLC) participants with wild type or unknown EGFR status. Participants will be observed from the start of treatment for 8 months or until death. The extension of the retrospective versus prospective observation will depend on the lag between the date of the participant enrollment and the date of beginning of erlotinib therapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedMay 2014
Primary CompletionJun 2016
TodayJul 2026
First PostedMay 8, 2014
Enrollment StartApr 30, 2014
Primary CompletionJun 10, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.2 years ago